Tirzepatide Bloodwork: 7 Labs to Track and Why
Tirzepatide is a dual GLP-1/GIP receptor agonist that affects multiple metabolic systems simultaneously: glucose metabolism, lipid processing, liver fat, thyroid signaling, and kidney function. Tracking the right labs tells you whether these effects are working as expected and catches problems before they become serious.
This guide covers which labs to run, when to run them, and what the numbers actually mean. For dosing protocols, see the Tirzepatide Dosing Guide. For a full overview of tirzepatide's metabolic effects, see Tirzepatide Benefits.
The Testing Timeline
Baseline (before starting): Run all 7 labs 1-2 weeks before your first dose. This is your reference point for everything.
Dose escalation check (week 8-12): Retest fasting glucose, liver enzymes, and lipase. You are titrating doses during this period — this catches safety issues early.
Mid-protocol (week 20-24): Retest A1c, fasting insulin, lipid panel, liver enzymes. By now you have been at or near maintenance dose long enough for A1c to reflect real changes.
Post-protocol (2-4 weeks after finishing): Retest everything. This tells you what improvements persist after discontinuation.
Lab 1: HbA1c (Glycated Hemoglobin)
Why It Matters Most for Tirzepatide
A1c is your broadest single indicator of metabolic improvement. It reflects average blood sugar over 2-3 months, smoothing out daily variation. Tirzepatide's dual mechanism — GLP-1 for insulin secretion and GIP for peripheral insulin sensitivity — produces A1c reductions of 1.87-2.07% in clinical trials (1).
Even if weight loss is your primary goal, A1c tells you whether the metabolic machinery is responding. A falling A1c means insulin resistance is improving, which drives fat loss and reduces long-term disease risk.
Optimal Ranges
| Status |
Range |
| Optimal |
< 5.0% |
| Excellent |
5.0-5.4% |
| Normal |
5.4-5.6% |
| Pre-diabetic |
5.7-6.4% |
| Diabetic |
6.5%+ |
Target on tirzepatide: Below 5.4% if non-diabetic. Below 6.0% if starting from diabetic range. SURPASS-1 showed 31-52% of T2D patients reached sub-5.7% on tirzepatide (1).
Lab 2: Fasting Glucose
What it measures: Blood sugar after 8-12 hours fasting.
Why it matters: Responds faster than A1c — you can see changes within 2-4 weeks. This is your early signal that tirzepatide is affecting glucose metabolism. It is also useful for monitoring between A1c tests.
| Status |
Range |
| Optimal |
72-85 mg/dL |
| Normal |
70-99 mg/dL |
| Pre-diabetic |
100-125 mg/dL |
| Diabetic |
126+ mg/dL |
Practical tip: If you have a home glucometer, check fasting glucose weekly during the first month. A consistent downward trend confirms the drug is active before the scale moves significantly.
Lab 3: Lipid Panel (Triglycerides, LDL, HDL)
Tirzepatide's metabolic effects extend broadly to lipid metabolism. As insulin resistance improves and body fat decreases, lipid profiles follow — with triglycerides typically being the most responsive marker.
| Marker |
Optimal |
Normal |
Concerning |
| Triglycerides |
< 80 mg/dL |
< 150 mg/dL |
> 200 mg/dL |
| LDL |
< 100 mg/dL |
< 130 mg/dL |
> 160 mg/dL |
| HDL |
> 60 mg/dL |
> 40 (M) / > 50 (F) |
< 40 mg/dL |
| Total Cholesterol |
< 200 mg/dL |
< 240 mg/dL |
> 240 mg/dL |
Triglycerides are often the first lipid marker to improve on GLP-1/GIP therapy. The SURMOUNT-1 post hoc analysis showed tirzepatide significantly reduced triglycerides and overall 10-year ASCVD risk across all dose groups (2).
ApoB is worth adding if available — it is a more accurate predictor of cardiovascular risk than LDL alone.
Lab 4: Liver Enzymes (ALT and AST)
Why They Matter
Tirzepatide reduces liver fat — the SURPASS-3 MRI substudy showed an 8.09% absolute reduction in liver fat content (3). This is a benefit, but it also means the liver is metabolically active. Monitoring ALT and AST confirms the positive trend and catches unexpected hepatic stress.
In the SYNERGY-NASH trial, most participants saw liver enzymes improve over time as liver fat cleared (4).
Optimal Ranges
| Marker |
Lab Reference |
Optimal |
Watch |
| ALT |
7-56 U/L |
< 25 U/L |
Rising trend or > 3x baseline |
| AST |
10-40 U/L |
< 25 U/L |
Rising trend or > 3x baseline |
Expected pattern: ALT/AST should trend downward over weeks 8-24 as liver fat clears. If they rise instead, especially above 3x your baseline, that is a red flag requiring evaluation.
Lab 5: Thyroid (Calcitonin and TSH)
The Most Overlooked Marker
This is the lab most people skip — and should not. GLP-1 receptor agonists carry a class warning for thyroid C-cell tumors based on rodent studies. While this has not been confirmed in humans at clinical durations, baseline and periodic thyroid monitoring is standard practice.
Calcitonin is produced by thyroid C-cells. Elevated calcitonin can indicate C-cell hyperplasia, which is the precursor to medullary thyroid carcinoma (MTC). This is a rare but serious concern.
TSH monitors overall thyroid function. Weight loss can affect thyroid hormone levels, and monitoring ensures thyroid function remains stable.
Optimal Ranges
| Marker |
Normal |
Optimal |
Investigate |
| Calcitonin |
< 10 pg/mL |
< 5 pg/mL |
> 10 pg/mL or rising trend |
| TSH |
0.4-4.0 mIU/L |
1.0-2.0 mIU/L |
< 0.4 or > 4.0 mIU/L |
Who must get this test: Anyone with personal or family history of medullary thyroid carcinoma or MEN 2 should not use tirzepatide (or any GLP-1 agonist) and must discuss with an endocrinologist.
Lab 6: Kidney Function (Creatinine and eGFR)
Why it matters: Appetite suppression can lead to reduced fluid intake and dehydration, which directly affects kidney markers. GLP-1 agonists have shown renal protective effects in some studies (semaglutide's FLOW trial demonstrated this), but monitoring is still prudent.
| Marker |
Optimal |
Normal |
Concerning |
| Creatinine |
0.7-1.2 mg/dL |
0.6-1.3 mg/dL |
> 1.3 mg/dL |
| eGFR |
> 90 mL/min |
> 60 mL/min |
< 60 mL/min |
| BUN |
7-18 mg/dL |
7-20 mg/dL |
> 20 mg/dL |
Practical note: Ensure adequate hydration while on tirzepatide. The appetite suppression can reduce both food and fluid intake. Aim for at least 2-3 liters of water daily, especially during the initial titration period when GI side effects may cause additional fluid loss.
Lab 7: Inflammatory Markers (hs-CRP)
What it measures: High-sensitivity C-reactive protein — a marker of systemic inflammation.
Why it matters: GLP-1 receptor agonists have demonstrated anti-inflammatory effects beyond what weight loss alone explains. Semaglutide reduced CRP by 39-60% in the STEP trials. Tirzepatide, with its additional GIP mechanism, likely produces similar or enhanced anti-inflammatory effects, though dedicated inflammation endpoint data is still emerging.
Tracking hs-CRP gives you a window into the broader metabolic improvement happening beyond the scale.
| Status |
Range |
| Optimal |
< 0.5 mg/L |
| Low risk |
< 1.0 mg/L |
| Average risk |
1.0-3.0 mg/L |
| High risk |
> 3.0 mg/L |
Putting It All Together: Sample Protocol
Week -1 (Baseline):
A1c, fasting glucose, fasting insulin, lipid panel, ALT, AST, lipase, TSH, calcitonin, creatinine/eGFR, hs-CRP.
Week 8-12 (Escalation check):
Fasting glucose, ALT, AST, lipase. These catch safety issues during dose titration.
Week 20-24 (Mid-protocol):
A1c, fasting insulin, lipid panel, ALT, AST, hs-CRP. These should show meaningful improvement by now.
Week 48+ (Post-protocol or annual):
Full panel retest. Compare every marker to baseline.
When to Stop: Red Flags
- Lipase > 3x ULN with abdominal pain -- possible pancreatitis, discontinue and seek care immediately
- ALT/AST > 5x ULN -- significant hepatic stress, discontinue
- Calcitonin rising above 10 pg/mL -- refer to endocrinology for thyroid evaluation
- eGFR declining below 60 -- evaluate hydration status, consider dose reduction
- Persistent severe GI symptoms despite dose reduction -- may not tolerate the drug
Frequently Asked Questions
Do I need bloodwork before starting tirzepatide?
Strongly recommended. Tirzepatide affects blood sugar, liver enzymes, lipids, thyroid markers, and kidney function. Baseline labs give you objective data to measure progress and catch potential issues early.
How soon after starting should I retest?
Run safety markers (liver enzymes, lipase, fasting glucose) at week 8-12 during dose escalation. Full panel retest at week 20-24 once you have been at maintenance dose long enough for A1c to reflect real changes.
What is the most important blood test for tirzepatide?
A1c is the best single efficacy marker. For safety, lipase (pancreatitis risk) and calcitonin (thyroid safety) are most critical. Most people track A1c but skip calcitonin -- do not make that mistake.
Will tirzepatide affect my liver enzymes?
Typically improves them. Tirzepatide reduces liver fat, which causes ALT and AST to trend downward over time. A sustained upward trend in liver enzymes is abnormal and warrants evaluation.
References
| Citation |
Topic |
PMID |
| 1. Rosenstock et al., Lancet (2021) |
SURPASS-1: tirzepatide monotherapy in T2D |
34186022 |
| 2. Sattar et al., Nat Med (2023) |
Tirzepatide and ASCVD risk: SURMOUNT-1 post hoc |
37932236 |
| 3. Hartman et al., Lancet Diabetes Endocrinol (2022) |
SURPASS-3 MRI: liver fat and adipose tissue |
35468325 |
| 4. Loomba et al., N Engl J Med (2024) |
SYNERGY-NASH: tirzepatide in MASH with fibrosis |
38856224 |
| 5. Jastreboff et al., N Engl J Med (2022) |
SURMOUNT-1: tirzepatide for weight management |
35658024 |
This guide is for educational and informational purposes only. It is not medical advice. The biomarker ranges described here reflect optimization targets used in functional and sports medicine — they are not diagnostic criteria. Lab results should be interpreted by a qualified healthcare provider.